0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TrkA

TrkA

Brief Information

Name:Nerve growth factor receptor Trk-A
Target Synonym:EC 2.7.10,Neurotrophic Receptor Tyrosine Kinase 1,Neurotrophic Tyrosine Kinase, Receptor, Type 1,Tropomyosin-Related Kinase A,P140-TrkA,Gp140trk,MTC,TRK,Oncogene TRK,EC 2.7.10.1,TRK1,Receptor, trkA,NTRK1,Neurotrophic tyrosine kinase receptor type 1,TRK1-t
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TRA-H5253 Human Human TrkA / NTRK1 (192-402) Protein, Mouse IgG2a Fc Tag
TRA-H5253-structure
TRA-H5253-sds
TRA-H5259 Human Human TrkA / NTRK1 (33-417) Protein, Mouse IgG2a Fc Tag
TRA-H5259-structure
TRA-H5259-sds

Synonym Name

TrkA,NTRK1,MTC,TRK,TRKA,Trk-A

Background

Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand. Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival. Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Regorafenib Monohydrate BAY-73-4506; DAST Approved Bayer Ag Stivarga, Resihance Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Solid tumours; Rectal Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
Larotrectinib sulfate ARRY-470; LOXO-101 Approved Array Biopharma Vitrakvi Japan Solid tumours Bayer Yakuhin Ltd 2018-11-26 Solid tumours; Neoplasms Details
Entrectinib NMS-E628; RXDX-101; RG-6268 Approved Nerviano Medical Sciences Rozlytrek EU Solid tumours; Carcinoma, Non-Small-Cell Lung Roche Registration Gmbh 2019-06-18 Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Thyroid Cancer, Papillary; Melanoma; Lymphoma, Large-Cell, Anaplastic; Hepatic Insufficiency; Colorectal Neoplasms; Sarcoma; Cholangiocarcinoma; Solid tumours; Brain Neoplasms; Neuroendocrine Tumors; Central Nervous System Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Head and Neck Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VMD-928 VMD-928 Phase 1 Clinical Vm Oncology Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Mesothelioma; Carcinoma, Adenoid Cystic; Prostatic Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma Details
Pegcantratinib CT 327; SNA-120; CT 301/P; K-252a-PEG2K; Pegylated K252A Phase 2 Clinical Cephalon Pruritus; Psoriasis; Neuralgia; Dermatitis, Atopic Details
Milciclib maleate PHA-125; TZLS-201; PHA-848125; PHA-848125C; PHA-848125AC Phase 2 Clinical Nerviano Medical Sciences, Tiziana Life Sciences Plc Liver Neoplasms; Thymoma; Glioma; Carcinoma, Hepatocellular Details
ACD-856 ACD-856 Phase 1 Clinical Alzecure Pharma Ab Alzheimer Disease Details
VM-902A VM-902; VM-902A Phase 2 Clinical Vm Discovery Pain Details
SNA-125 CT-340; SNA-125 Phase 2 Clinical Sienna Biopharmaceuticals, Creabilis Pruritus; Psoriasis; Dermatitis, Atopic Details
AK-1830 AK-1830 Phase 1 Clinical Array Biopharma Inflammation Details
PLX-7486 PLX-7486; PLX7486-TsOH Phase 1 Clinical Daiichi Sankyo Co Ltd Giant Cell Tumor of Tendon Sheath; Solid tumours; Pancreatic Neoplasms Details
BN-201 BN-201 Phase 1 Clinical Bionure Optic Neuritis; Demyelinating Diseases; Neuromyelitis Optica Details
HG-030 HG-030 Phase 1 Clinical Hitgen Inc Solid tumours Details
HH-30134 Phase 1 Clinical Solid tumours; Neoplasms Details
Lestaurtinib SP-924; CEP-701; KT-5555; SPM-924; A-154475.0 Phase 3 Clinical Kyowa Hakko Kirin Leukemia, Myeloid; Bone Marrow Neoplasms; Polycythemia Vera; Prostatic Neoplasms; Psoriasis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Thrombocythemia, Essential Details
Altiratinib DP-5164; DCC-2701; DCC-22701; T-678746713 Phase 1 Clinical Deciphera Solid tumours; Neoplasms Details
PBI-200 Phase 2 Clinical Pyramid Biosciences Solid tumours; Desmoplastic Small Round Cell Tumor; Brain Neoplasms Details
Taletrectinib DS-6051b; DS-6051a; DS-6051; AB-106 Phase 2 Clinical Daiichi Sankyo Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
XZP-5955 XZP-5955 Phase 2 Clinical Xuanzhu Biological Technology Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
Repotrectinib TPX-0005 Phase 3 Clinical Turning Point Therapeutics Solid tumours; Central Nervous System Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop